X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (44440) 44440
Publication (5026) 5026
Book Review (864) 864
Book Chapter (376) 376
Book / eBook (270) 270
Conference Proceeding (90) 90
Dissertation (46) 46
Reference (23) 23
Newsletter (16) 16
Magazine Article (9) 9
Data Set (5) 5
Newspaper Article (4) 4
Paper (3) 3
Transcript (2) 2
Presentation (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (23600) 23600
humans (23071) 23071
index medicus (22345) 22345
male (17725) 17725
rats (11653) 11653
female (10141) 10141
hypertension (7666) 7666
pharmacology & pharmacy (7510) 7510
mice (5863) 5863
middle aged (5789) 5789
angiotensin (5461) 5461
blood pressure - drug effects (4755) 4755
peripheral vascular disease (4732) 4732
aged (4605) 4605
physiology (4584) 4584
cardiac & cardiovascular systems (4527) 4527
expression (4349) 4349
hypertension - drug therapy (4212) 4212
rats, sprague-dawley (4050) 4050
receptor (3937) 3937
blood-pressure (3626) 3626
cells, cultured (3618) 3618
adult (3597) 3597
angiotensin ii (3581) 3581
angiotensin ii type 1 receptor blockers - therapeutic use (3581) 3581
cell biology (3549) 3549
biochemistry & molecular biology (3480) 3480
endocrinology & metabolism (3391) 3391
angiotensin-converting enzyme inhibitors - therapeutic use (3292) 3292
research (3277) 3277
oxidative stress (3221) 3221
receptors (3216) 3216
signal transduction (3213) 3213
angiotensin ii - pharmacology (3198) 3198
dose-response relationship, drug (3172) 3172
blood pressure (3143) 3143
inflammation (3140) 3140
risk factors (3089) 3089
angiotensin-ii (3045) 3045
analysis (2993) 2993
angiotensin ii type 1 receptor blockers - pharmacology (2982) 2982
physiological aspects (2942) 2942
rats, wistar (2915) 2915
treatment outcome (2910) 2910
activation (2899) 2899
neurosciences (2850) 2850
disease models, animal (2798) 2798
rodents (2760) 2760
article (2753) 2753
diabetes (2748) 2748
heart failure (2738) 2738
renin-angiotensin system (2731) 2731
urology & nephrology (2726) 2726
proteins (2722) 2722
antihypertensive agents - therapeutic use (2720) 2720
angiotensin receptor antagonists (2665) 2665
renin-angiotensin system - drug effects (2590) 2590
medicine (2572) 2572
hypertension - physiopathology (2563) 2563
medicine & public health (2470) 2470
time factors (2373) 2373
health aspects (2326) 2326
gene expression (2288) 2288
losartan (2225) 2225
tetrazoles - pharmacology (2192) 2192
mortality (2175) 2175
signal transduction - drug effects (2118) 2118
care and treatment (2055) 2055
medicine, research & experimental (2025) 2025
drug therapy (2019) 2019
drug therapy, combination (1981) 1981
research article (1976) 1976
heart-failure (1969) 1969
losartan - pharmacology (1961) 1961
phosphorylation (1944) 1944
inhibition (1932) 1932
mice, inbred c57bl (1931) 1931
cells (1919) 1919
atherosclerosis (1900) 1900
tetrazoles - therapeutic use (1855) 1855
antihypertensive agents - pharmacology (1854) 1854
fibrosis (1849) 1849
heart (1836) 1836
gene-expression (1835) 1835
apoptosis (1830) 1830
receptor, angiotensin, type 1 - metabolism (1805) 1805
multidisciplinary sciences (1804) 1804
cardiology (1762) 1762
angiotensin-converting enzyme inhibitors - pharmacology (1761) 1761
disease (1759) 1759
angiotensin ii - metabolism (1753) 1753
enzymes (1737) 1737
internal medicine (1720) 1720
smooth-muscle-cells (1687) 1687
receptor, angiotensin, type 1 (1642) 1642
rna, messenger - metabolism (1610) 1610
heart failure - drug therapy (1599) 1599
system (1575) 1575
nitric-oxide (1573) 1573
imidazoles - pharmacology (1550) 1550
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (203) 203
UofT at Mississauga - Stacks (15) 15
Collection Dvlpm't (Acquisitions) - Closed Orders (10) 10
UTL at Downsview - May be requested (10) 10
Online Resources - Online (8) 8
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
UofT at Scarborough - Stacks (7) 7
Chemistry (A D Allen) - Stacks (2) 2
Dentistry (Harry R Abbott) - Stacks (1) 1
Gerstein Science - Periodical Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Trinity College (John W Graham) - Storage (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (44464) 44464
Japanese (520) 520
German (155) 155
Chinese (107) 107
Russian (73) 73
Spanish (67) 67
French (59) 59
Italian (14) 14
Polish (13) 13
Portuguese (12) 12
Korean (9) 9
Czech (8) 8
Hungarian (8) 8
Turkish (7) 7
Ukrainian (6) 6
Danish (5) 5
Dutch (5) 5
Swedish (5) 5
Norwegian (4) 4
Serbian (4) 4
Arabic (2) 2
Hebrew (2) 2
Romanian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
European Heart Journal, ISSN 0195-668X, 12/2012, Volume 33, Issue 23, pp. 2980 - 2990
Journal Article
Circulation: Heart Failure, ISSN 1941-3289, 09/2012, Volume 5, Issue 5, pp. 627 - 634
Background-TRV120027 is a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor; it antagonizes canonical G-protein-mediated coupling while,... 
Heart failure | Receptors | Animal models of human disease | Cardiovascular pharmacology | β-arrestin | Angiotensin II | PATHWAYS | heart failure | ACTIVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | PROTEIN | animal models of human disease | receptors | BETA-ARRESTIN-2 | beta-arrestin | KINASE | ADRENERGIC-RECEPTOR | cardiovascular pharmacology | BLOOD-PRESSURE | INHIBITION | angiotensin II | Furosemide - administration & dosage | Heart Failure - physiopathology | Urodynamics - drug effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Arrestins - metabolism | Atrial Natriuretic Factor - blood | Glomerular Filtration Rate - drug effects | Kidney - metabolism | Time Factors | Arterial Pressure - drug effects | Vascular Resistance - drug effects | Renal Circulation - drug effects | Receptor, Angiotensin, Type 1 - drug effects | Drug Therapy, Combination | Kidney - physiopathology | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Disease Models, Animal | Heart - physiopathology | Diuretics - administration & dosage | Kidney - drug effects | Natriuresis - drug effects | Diuretics - pharmacology | Heart Failure - metabolism | Cardiac Pacing, Artificial | Heart Failure - drug therapy | Diuresis - drug effects | Animals | Signal Transduction - drug effects | beta-Arrestins | Receptor, Angiotensin, Type 1 - metabolism | Dogs | Pulmonary Wedge Pressure - drug effects | Heart - drug effects | Ligands | Oligopeptides - administration & dosage | Infusions, Intravenous | Furosemide - pharmacology | Oligopeptides - pharmacology
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 07/2008, Volume 28, Issue 7, pp. 1263 - 1269
OBJECTIVE—Resveratrol (3,5,4′-trihydroxystilbene), a polyphenol found in red wine, is known to activate sirtuin1 (SIRT1), a longevity gene. Previous studies... 
Vascular smooth muscle cell | Angiotensin II receptor | SIRT1 | Resveratrol | SURVIVAL | LIFE-SPAN | ACTIVATION | TRANSCRIPTION | FAMILY | ELEMENT | INHIBITION | CLONING | PERIPHERAL VASCULAR DISEASE | vascular smooth muscle cell | HEMATOLOGY | resveratrol | HISTONE DEACETYLASE | angiotensin II receptor | Transcription, Genetic - drug effects | Antihypertensive Agents - pharmacology | Sp1 Transcription Factor - metabolism | Aorta - metabolism | Stilbenes - pharmacology | Promoter Regions, Genetic - drug effects | RNA, Messenger - metabolism | Dose-Response Relationship, Drug | Receptor, Angiotensin, Type 1 - genetics | Transfection | Time Factors | Sirtuin 1 | Hypertension - chemically induced | Hypertension - prevention & control | Receptor, Angiotensin, Type 1 - drug effects | Angiotensin II | Myocytes, Smooth Muscle - drug effects | Sirtuins - genetics | Disease Models, Animal | Muscle, Smooth, Vascular - drug effects | Myocytes, Smooth Muscle - enzymology | Aorta - drug effects | Down-Regulation | Mice, Inbred C57BL | Cells, Cultured | Enzyme Inhibitors - pharmacology | Rats | Rats, Sprague-Dawley | Hypertension - metabolism | Animals | Receptor, Angiotensin, Type 1 - metabolism | Renin-Angiotensin System - drug effects | Mice | Niacinamide - pharmacology | Muscle, Smooth, Vascular - enzymology | Sirtuins - metabolism | Index Medicus
Journal Article
Journal Article
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 2016, Volume 311, Issue 4, pp. H871 - H880
We previously reported that endoplasmic reticulum (ER) stress is induced in the subfornical organ (SFO) and the hypothalamic paraventricular nucleus (PVN) of... 
Heart failure | Brain | Sympathetic activity | Hypothalamic paraventricular nucleus | Mitogen-activated protein kinase | Subfornical organ | Endoplasmic reticulum stress | heart failure | ACTIVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | INDUCED PHOSPHORYLATION | MYOCARDIAL-INFARCTION | ER STRESS | subfornical organ | KINASE | RATS | sympathetic activity | KAPPA-B | brain | endoplasmic reticulum stress | hypothalamic paraventricular nucleus | mitogen-activated protein kinase | UNFOLDED PROTEIN RESPONSE | PERIPHERAL VASCULAR DISEASE | UP-REGULATION | Cholagogues and Choleretics - pharmacology | Tumor Necrosis Factor-alpha - genetics | Heart Failure - physiopathology | Male | NF-KappaB Inhibitor alpha - genetics | Peptidyl-Dipeptidase A - drug effects | Interleukin-1beta - genetics | Sympathetic Nervous System - physiopathology | RNA, Messenger - metabolism | Activating Transcription Factor 6 - genetics | Subfornical Organ - drug effects | Brain - metabolism | Heat-Shock Proteins - genetics | Inflammation - metabolism | Receptor, Angiotensin, Type 1 - genetics | Cyclooxygenase 2 - genetics | p38 Mitogen-Activated Protein Kinases - metabolism | Real-Time Polymerase Chain Reaction | Echocardiography | Signal Transduction | Rats | Cyclooxygenase 2 - drug effects | Heart Failure - metabolism | Rats, Sprague-Dawley | Blotting, Western | Brain - drug effects | Tumor Necrosis Factor-alpha - drug effects | Mitogen-Activated Protein Kinase 3 - metabolism | Endoplasmic Reticulum Stress | Paraventricular Hypothalamic Nucleus - metabolism | Infusions, Intraventricular | Mitogen-Activated Protein Kinases - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | Interleukin-1beta - drug effects | Sympathetic Nervous System - drug effects | Mitogen-Activated Protein Kinase 1 - drug effects | X-Box Binding Protein 1 - drug effects | Sympathetic Nervous System - metabolism | Transcription Factor RelA - genetics | Activating Transcription Factor 6 - drug effects | Mitogen-Activated Protein Kinase 3 - drug effects | Taurochenodeoxycholic Acid - pharmacology | Peptidyl-Dipeptidase A - genetics | Renin-Angiotensin System | Receptor, Angiotensin, Type 1 - drug effects | RNA, Messenger - drug effects | Subfornical Organ - metabolism | Heat-Shock Proteins - drug effects | Activating Transcription Factor 4 - genetics | Activating Transcription Factor 4 - drug effects | NF-KappaB Inhibitor alpha - drug effects | Paraventricular Hypothalamic Nucleus - drug effects | p38 Mitogen-Activated Protein Kinases - drug effects | Animals | Transcription Factor RelA - drug effects | X-Box Binding Protein 1 - genetics | Mitogen-Activated Protein Kinases - metabolism | Physiological aspects | Cellular signal transduction | Endoplasmic reticulum | Health aspects | Mitogen-activated protein kinases | Cardiovascular Neurohormonal Regulation
Journal Article
Cancer Letters, ISSN 0304-3835, 2014, Volume 355, Issue 1, pp. 46 - 53
Abstract Gastric cancer with peritoneal dissemination has poor clinical prognosis because of the presence of rich stromal fibrosis and acquired drug... 
Hematology, Oncology and Palliative Medicine | TGF-β | Peritoneal dissemination | Angiotensin II | Gastric cancer | Fibrosis | TUMOR PROGRESSION | INTRAPERITONEAL DOCETAXEL | PERITONEAL CARCINOMATOSIS | MESOTHELIAL CELLS | EPITHELIAL-MESENCHYMAL TRANSITION | TGF-beta | LYMPH-NODE METASTASIS | ONCOLOGY | TRANSFORMING GROWTH-FACTOR-BETA-1 | NF-KAPPA-B | THROMBOSPONDIN-1 PRODUCTION | Tetrazoles - pharmacology | Stromal Cells - pathology | Humans | Transforming Growth Factor beta1 - metabolism | Stomach Neoplasms - metabolism | Epithelial-Mesenchymal Transition - drug effects | Stomach Neoplasms - pathology | Angiotensin II Type 1 Receptor Blockers - pharmacology | Dose-Response Relationship, Drug | Omentum - drug effects | Time Factors | Stromal Cells - drug effects | Female | Antineoplastic Agents - pharmacology | Receptor, Angiotensin, Type 1 - drug effects | Stromal Cells - metabolism | Omentum - metabolism | Stomach Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Tumor Burden - drug effects | Mice, Nude | Receptor, Angiotensin, Type 1 - metabolism | Cell Line, Tumor | Omentum - pathology | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Mice, Inbred BALB C | Transforming growth factors | Candesartan | Stomach cancer | Angiotensin | Cancer | Studies | Cell growth | Medical prognosis | Metastasis | Cancer therapies | Tumors
Journal Article
Trends in Cardiovascular Medicine, ISSN 1050-1738, 2015, Volume 26, Issue 3, pp. 221 - 228
Abstract Angiotensin II, an important component of renin angiotensin system, is a potent vasopressor and its actions are mostly mediated via angiotensin II... 
Cardiovascular | Heart failure | Hypertension | Renin angiotensin system | Angiotensin receptor blocker | Diabetes mellitus | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTAGONIST | CLINICAL-TRIAL | HEART-FAILURE | DIABETIC-NEPHROPATHY | HYPERTENSIVE PATIENTS | AZILSARTAN MEDOXOMIL | FIMASARTAN | OLMESARTAN | IRBESARTAN | VALSARTAN | Kidney Diseases - physiopathology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Heart Diseases - metabolism | Kidney - pathology | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Receptor, Angiotensin, Type 2 - drug effects | Kidney - metabolism | Drug Interactions | Myocardium - metabolism | Receptor, Angiotensin, Type 1 - drug effects | Drug Therapy, Combination | Kidney Diseases - metabolism | Heart - physiopathology | Kidney - drug effects | Angiotensin II - metabolism | Heart Diseases - physiopathology | Kidney Diseases - drug therapy | Treatment Outcome | Angiotensin II Type 2 Receptor Blockers - adverse effects | Angiotensin II Type 2 Receptor Blockers - therapeutic use | Animals | Receptor, Angiotensin, Type 2 - metabolism | Receptor, Angiotensin, Type 1 - metabolism | Heart - drug effects | Renin-Angiotensin System - drug effects | Heart Diseases - drug therapy | Heart | Pharmacy | Angiotensin converting enzyme | Atherosclerosis | Angiotensin | Physiological aspects | Patient compliance | Studies | Cardiac arrhythmia | Advantages | Cardiomyopathy | Mortality | Inflammation | Diabetes | Kidney diseases | Metabolism
Journal Article
Circulation, ISSN 0009-7322, 08/2004, Volume 110, Issue 9, pp. 1103 - 1107
Background-Experimental studies revealed proinflammatory properties of angiotensin II. We evaluated antiinflammatory effects of the angiotensin II subtype 1... 
Hypertension | Inflammation | Cholesterol | Angiotensin | Atherosclerosis | atherosclerosis | C-REACTIVE PROTEIN | CARDIAC & CARDIOVASCULAR SYSTEMS | WEIGHT-LOSS | PREVENTION | RANDOMIZED-TRIAL | RISK | HUMAN ENDOTHELIAL-CELLS | INFLAMMATORY MARKERS | DENSITY-LIPOPROTEIN CHOLESTEROL | inflammation | angiotensin | CARDIOVASCULAR-DISEASE | cholesterol | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | hypertension | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Prospective Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cholesterol - blood | Humans | Middle Aged | Imidazoles - administration & dosage | Hypertension - drug therapy | Male | Vasculitis - complications | Diabetes Mellitus, Type 2 - epidemiology | Hypertension - blood | Arteriosclerosis - epidemiology | Interleukin-6 - blood | Tetrazoles - administration & dosage | Lipids - blood | Female | Intercellular Adhesion Molecule-1 - blood | Imidazoles - therapeutic use | Receptor, Angiotensin, Type 1 - drug effects | Arteriosclerosis - blood | C-Reactive Protein - analysis | Drug Therapy, Combination | Pravastatin - therapeutic use | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Olmesartan Medoxomil | Vasculitis - blood | Double-Blind Method | Comorbidity | Treatment Outcome | Chemokine CCL2 - blood | Tumor Necrosis Factor-alpha - analysis | Diabetes Mellitus, Type 2 - blood | Pravastatin - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Vasculitis - drug therapy | Biomarkers | Hypertension - complications | Tetrazoles - therapeutic use | Aged
Journal Article
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 07/2014, Volume 307, Issue 2, pp. H191 - H198
This study investigated sex differences in the sensitization of angiotensin (ANG) II-induced hypertension and the role of central estrogen and ANG-(1-7) in... 
Blood pressure | Angiotensin II | Angiotensin-(1-7) | Sex difference | Central nervous system | blood pressure | CONVERTING ENZYME | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | sex difference | BEHAVIORAL SENSITIZATION | RECEPTOR | 17-BETA-ESTRADIOL | central nervous system | EPIGENETICS | FEMALE RATS | angiotensin II | angiotensin-(1-7) | ALDOSTERONE/NACL-INDUCED HYPERTENSION | PERIPHERAL VASCULAR DISEASE | CENTRAL-NERVOUS-SYSTEM | SEX-DIFFERENCES | EXPRESSION | Estrogen Replacement Therapy | Angiotensin II - administration & dosage | Receptors, G-Protein-Coupled - metabolism | Male | RNA, Messenger - metabolism | Brain - metabolism | Peptidyl-Dipeptidase A - genetics | Receptor, Angiotensin, Type 1 - genetics | Time Factors | Peptidyl-Dipeptidase A - metabolism | Hypertension - prevention & control | Female | Blood Pressure - drug effects | Hypertension - genetics | Receptor, Angiotensin, Type 1 - drug effects | Receptors, G-Protein-Coupled - drug effects | Disease Models, Animal | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - drug effects | Ovariectomy | Brain - physiopathology | Peptide Fragments - administration & dosage | Angiotensin I - administration & dosage | Estradiol - administration & dosage | Gene Expression Regulation | Rats | Proto-Oncogene Proteins - genetics | Renin-Angiotensin System - genetics | Angiotensin II - analogs & derivatives | Telemetry | Rats, Sprague-Dawley | Hypertension - physiopathology | Hypertension - metabolism | Brain - drug effects | Animals | Receptor, Angiotensin, Type 1 - metabolism | Sex Factors | Renin-Angiotensin System - drug effects | Receptors, G-Protein-Coupled - genetics | Infusions, Intraventricular | Physiological aspects | Medicine, Experimental | Medical research | Properties | Renin-angiotensin system | Estrogen | Cardiovascular Neurohormonal Regulation | angiotensin-(1–7), central nervous system
Journal Article
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, ISSN 0363-6119, 04/2008, Volume 294, Issue 4, pp. 1220 - 1226
The purpose of this review is to examine sex differences in response to stimulation and inhibition of the renin-angiotensin system (RAS). The RAS plays a... 
Angiotensin-converting enzyme inhibitors | Janus kinase/signal transducers and activators of transcription | Angiotensin receptor blocker | Nuclear factor-κβ | Transforming growth factor-β | COLLAGEN GENE-TRANSCRIPTION | angiotensin-converting enzyme inhibitors | PHYSIOLOGY | TGF-BETA | SPONTANEOUSLY HYPERTENSIVE-RATS | nuclear factor-kappa B | janus kinase/signal transducers and activators of transcription | angiotensin receptor blocker | transforming growth factor-beta | GROWTH-FACTOR-BETA | II-INDUCED HYPERTENSION | ENZYME-RELATED CARBOXYPEPTIDASE | NITRIC-OXIDE | GENDER-DIFFERENCES | SMOOTH-MUSCLE CELLS | CONVERTING-ENZYME | Kidney Diseases - physiopathology | Estradiol - metabolism | Angiotensin II - metabolism | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Kidney Diseases - drug therapy | Receptor, Angiotensin, Type 2 - drug effects | Male | Treatment Outcome | Angiotensin II Type 1 Receptor Blockers - pharmacology | Kidney - metabolism | Receptor, Angiotensin, Type 2 - metabolism | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Signal Transduction - drug effects | Receptor, Angiotensin, Type 1 - metabolism | Sex Factors | Female | Renin-Angiotensin System - drug effects | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Receptor, Angiotensin, Type 1 - drug effects | Chronic Disease | Kidney Diseases - metabolism
Journal Article
Journal Article